Beauty & Skincare

Period Blood Diagnostics: A Breakthrough in Women’s Health

Every month, nearly two billion people around the world menstruate. Most discard their menstrual blood—what scientists now believe holds vital clues about women’s health. Source: allure.com.

Menstrual Blood: A Hidden Health Signal

Menstrual effluent—what comes out during a period—contains more than just blood. It includes uterine lining, vaginal secretions, and stem cells. This complex mixture is not merely a byproduct of the reproductive cycle; it is a dynamic biological fluid that reflects the state of the endometrium, the inner lining of the uterus, and the broader physiological environment of the body.

Medical research has identified over 1,000 distinct proteins in menstrual blood. About 385 of these proteins are unique to menstrual fluid and are not found in any other blood sample. This specificity makes menstrual blood a unique biological resource. These proteins serve as biomarkers that can signal changes in the health of the uterus and broader systems such as the immune system, metabolic function, and inflammatory responses.

Dr. Gemma Sharp, a professor of epidemiology at the University of Exeter and director of the Menarche Menstruation Menopause and Mental Health Consortium, emphasizes that the information contained in menstrual blood offers a direct window into the health of the reproductive system. ‘There’s a whole host of potentially really important information about the health of the uterus itself and also our body’s broader health and wellbeing,’ she says. ‘It’s like having a real-time snapshot of what’s happening inside the body during a monthly cycle.’

Sharp’s work is part of a larger initiative to build a large-scale menstrual fluid biobank. This biobank aims to collect and analyze samples from thousands of women to identify patterns and correlations between menstrual fluid composition and various health conditions, including endometriosis, infertility, and systemic inflammation.

Why Has This Been Overlooked?

For decades, women’s health has been underrepresented in medical research. Before 1993, clinical trials often excluded women. The National Institutes of Health only mandated gender inclusion in federally funded studies that year. This historical exclusion has left a significant gap in understanding how diseases and treatments affect women. As a result, data on women’s health has been limited to just over three decades—far too short a period to establish robust, long-term insights into conditions that manifest over years or decades.

Even among medical professionals, menstruation remains poorly understood. Dr. Ridhi Tariyal, co-founder of NextGen Jane, recalls pitching her menstrual blood research to a male oncologist. He was enthusiastic about the idea of analyzing tampons for DNA. When she explained that women typically change tampons every few hours—due to the flow and absorption characteristics—she responded, ‘Actually, there’s not just one tampon during a period, we change it every few hours.’ He paused and said, ‘Really?’ This reaction underscores a broader issue: many medical practitioners lack foundational knowledge about the menstrual cycle, despite it being a central part of human biology.

Medical education systems have historically emphasized male physiology and disease models, with little attention to female-specific biology. This imbalance has led to a persistent gap in clinical training. As Tariyal notes, ‘It’s not just about knowledge—it’s about representation. If doctors don’t understand what women go through, how can they provide appropriate care?’

The Stigma of Menstrual Blood

Menstrual blood has long carried a social stigma. In most cultures, it is perceived as impure, unclean, or even dangerous. Dr. Christine Metz, a professor of medicinal biochemistry at the Feinstein Institute for Medical Research, states that no known culture outside indigenous communities embraces menstrual blood as a natural or sacred element. ‘Everyone else says, “we don’t talk about that stuff,”’ she says. This cultural silence has contributed to a deep-seated taboo that persists in both public discourse and medical settings.

The roots of this stigma can be traced to historical and religious narratives. In the 1976 film Carrie, menstruation is portrayed as a curse that leads to rage and destruction—exaggerated for dramatic effect, but deeply resonant with real-life experiences. The film’s depiction of ‘free bleeding’ as a form of supernatural violence has cemented a cultural image of menstruation as something revolting and sinful. This narrative has been repeated in popular media, from horror films to comedy sketches, often reducing menstruation to a gross-out trope rather than a natural biological process.

Image from the original article
original publisher image. Via original publisher. · Source

Decades ago, the idea of free bleeding at the London Marathon would have been unthinkable. Today, however, such imagery is increasingly being challenged. Period products have evolved significantly. Brands like Thinx, Looni, and Cora now offer period underwear, menstrual cups, and cycle-support garments. These innovations reflect a shift in cultural perception—from shame to empowerment. Shows like Broad City and Turning Red use menstruation as a metaphor for transition, identity, and resilience. In Turning Red, a red panda symbolizes the emotional and physical changes of adolescence, with menstruation serving as a pivotal moment of self-discovery.

Despite these cultural shifts, stigma persists. Period poverty—defined as the inability to afford period products—remains a global issue, particularly in low- and middle-income countries. This lack of access not only affects hygiene and dignity but also impacts health outcomes, including increased risks of infection and poor mental well-being.

From Crime Scenes to Diagnostics

Menstrual blood research began not in a laboratory, but in a crime scene investigation. In 2012, New York City’s Office of the Chief Medical Examiner faced a common legal defense: ‘The blood stains in the apartment aren’t from a violent crime—they’re from menstruation.’ This so-called ‘menstrual blood defense’ has been used in legal cases to challenge the authenticity of bloodstain evidence.

To counter this, forensic scientist Donald Siegel and his team conducted a study to determine whether menstrual blood could be chemically distinguished from systemic blood. Their analysis revealed that menstrual effluent contains hundreds of unique proteins—many of which are not present in any other bodily fluid. This discovery laid the foundation for the idea that menstrual blood could serve as a diagnostic tool.

Once the chemical distinction was established, researchers began to explore whether menstrual blood could detect health conditions more effectively than traditional blood samples. The earliest application of this concept was in diabetes monitoring. Hemoglobin A1C, a standard test used to track blood sugar levels, was found to be measurable in menstrual blood. This opened the door for a non-invasive alternative to finger-prick tests.

Qvin, a California-based health tech company founded in 2014 by Dr. Sara Naseri and Soren Therkelsen, was the first to commercialize this idea. In 2024, their Q-pad received FDA approval to measure hemoglobin A1C using menstrual blood. The Q-pad is a menstrual pad with a removable collection strip that users mail in for analysis. While this innovation was a milestone, it did not address a major user pain point: the inconvenience of mailing a tampon or pad to a lab. A finger-prick at home is generally less burdensome than the process of collecting, storing, and mailing a product.

Qvin has since pivoted to focus on human papillomavirus (HPV) testing. HPV is a common virus that can lead to cervical cancer, and current testing requires a speculum exam—many women find this uncomfortable or intimidating. Qvin’s diagnostic pads, which use menstrual blood to detect HPV, have received approval from Thailand’s Food and Drug Administration. This shift demonstrates how menstrual blood could be used not just for metabolic conditions, but for preventive gynecological screening.

How Menstrual Blood Can Reveal Reproductive Health

Menstrual blood is a direct sample of the endometrium—the innermost lining of the uterus. This makes it a unique proxy for studying reproductive health. Unlike venous blood, which is a systemic sample, menstrual blood reflects the immediate environment of the uterine lining. This proximity allows researchers to detect biomarkers that are specific to the reproductive system.

Dr. Irma Vlasac, a researcher at the Geisel School of Medicine at Dartmouth, notes that menstrual blood contains immune cells that are specific to the uterus. These cells are not found in other parts of the body and may play a role in regulating inflammation and tissue repair. In conditions such as endometriosis and reproductive tract cancers, these immune cells may provide early signals of disease presence or progression.

Dr. Metz has long studied inflammation markers in the endometrium. In the mid-1990s, she began by collecting umbilical cord tissue from labor and delivery units. She observed how the cells in the umbilical cord responded to inflammatory stimuli. This led her to consider menstrual blood as a more accessible and repeatable source. Her team has since built a large biobank of menstrual samples, allowing them to study how inflammation progresses over time in women with reproductive disorders.

One of the key proteins they have identified is urocortin 3—a hormone involved in the body’s inflammatory response. This is particularly relevant for conditions like endometriosis, where inflammation is a central feature.

Image from the original article
original publisher image. Via original publisher. · Source

Endometriosis: A Condition Without a Test

Endometriosis affects over 6 million women in the United States. It causes severe pain, fatigue, and fertility challenges. However, there is no reliable, non-invasive test for the condition. Diagnosis currently relies on laparoscopic surgery, a procedure that detects only about 70% of all cases. Many women wait years—sometimes decades—before receiving a diagnosis, often leading to significant physical and emotional distress.

Dr. Metz’s ROSE (Research Outsmarts Endometriosis) study, launched in 2013, has enrolled nearly 4,000 women. The study collects and analyzes menstrual blood to identify biomarkers linked to endometriosis. So far, the team has identified specific cells in menstrual blood that express inflammatory markers predictive of the condition. These markers are not present in healthy women, suggesting a potential for early detection.

One of the most critical findings is the optimal method for sample collection. The ROSE team discovered that silicon menstrual cups are the most effective method for collecting menstrual blood. This is because absorbent products like tampons and pads destroy cells and interfere with the integrity of the sample. In contrast, a silicon cup allows for the collection of about a teaspoon of fluid during peak flow—enough to preserve cells and proteins for analysis.

This funding reflects growing recognition that menstrual blood research is not just a niche interest, but a legitimate and promising field of medical inquiry.

Other Companies and Research Efforts

NextGen Jane, an Oakland-based women’s health and biotech company, is developing a home-based test using tampons. The company has completed a study on endometriosis and is now enrolling patients with infertility and autoimmune disorders such as lupus and hidradenitis. Since menstruation is an inflammatory process, these conditions are ideal for study using menstrual fluid as a biomarker.

Endogene.bio, a research team at the Hospital Clinic in Barcelona, is also studying endometriosis using menstrual blood samples. Their work focuses on identifying patterns in protein expression that distinguish endometriotic tissue from healthy tissue.

At ETH Zurich, a renowned public research university in Switzerland, researchers have developed a diagnostic menstrual pad in early clinical testing. This pad is designed to detect markers for cancer, endometriosis, and general inflammation. While still in the testing phase, the technology represents a significant step toward accessible, non-invasive diagnostics.

This fund will support research into endometriosis and other gynecological disorders, as well as chronic systemic inflammatory diseases that disproportionately affect women. The fund aims to bridge the research gap by providing financial support to scientists and innovators in the field.

These efforts suggest that menstrual blood could help diagnose not just endometriosis, but also uterine fibroids, endometrial hyperplasia, adenomyosis, premenstrual dysphoric disorder (PMDD), and fertility issues. Dr. Kelly Lacob, CEO of Xella Health, envisions that menstrual fluid data could reveal vital information about the ovarian environment—offering insights into both the quantity and quality of eggs, a frequent blind spot in fertility care.

Limitations and Scientific Concerns

Despite promising developments, many researchers caution against overhype. Dr. Metz warns that artificial intelligence (AI)-powered diagnostics in menstrual blood are only as good as their training data. There is currently little published literature on menstrual blood, so AI models may lack sufficient data to make reliable predictions.

Image from the original article
original publisher image. Via original publisher. · Source

Xella Health uses AI to analyze lab results and recommend follow-up actions. Its bot is trained on female-specific clinical guidelines, published literature, and clinical resources. It flags abnormal values and detects patterns, but it does not replace human review. The AI system is designed to identify risks and provide clinical context, not to make definitive diagnoses.

Some researchers fear that companies may launch products before robust clinical trials prove their accuracy. There is currently no evidence that menstrual blood testing is more accurate than traditional methods for diagnosing endometriosis or other conditions. Without large-scale, randomized, controlled trials, claims about diagnostic power remain speculative.

Dr. Metz stresses that validation requires large, rigorous trials. These trials must test for reproducibility, precision, accuracy, and robustness. Without such evidence, any claims about the diagnostic power of menstrual blood must be treated with caution. Investors are already wary. A failure in a product or study could damage public trust in women’s health innovations.

Why This Matters for Women’s Health

Menstruation is a natural process of tissue repair and regeneration. Each month, the uterus sheds and regenerates its lining—without fibrosis, or excessive scar tissue. This process is a remarkable demonstration of how the body heals itself without forming permanent scars.

Dr. Tariyal calls this a ‘model system’ for studying how the body heals. ‘Every month, the body performs a scarless regeneration of the endometrium,’ she says. ‘This is a unique opportunity to observe how the body moves from injury to repair without fibrosis. We have just not spent enough time studying it.’

Understanding this process could lead to breakthroughs in regenerative medicine, wound healing, and tissue engineering. If scientists can decode the mechanisms behind scarless healing in the uterus, they may be able to apply those principles to other parts of the body—potentially revolutionizing treatments for injuries and chronic diseases.

Yet, funding for women’s health remains critically low. In 2020, only 5% of global R&D; funding was allocated to women’s health. Of that, just 1% went to women-specific conditions such as endometriosis, contraception, maternal health, and fertility. A quarter of that 1% was restricted solely to fertility. This funding gap limits research, innovation, and access to new diagnostics and treatments.

Dr. Gemma Sharp believes that combining large-scale data collection with rigorous scientific research could accelerate progress. ‘If we can combine those two things and get the rigor and the scale, then I actually think that the innovations will come thick and fast,’ she predicts. She emphasizes that fem-tech platforms have the potential to reach millions of women, but only if they are grounded in solid, evidence-based science.

Dr. Metz remains hopeful. She believes the market is large enough to accommodate multiple diagnostic approaches—provided they are accurate and reproducible. ‘We need to move forward with caution,’ she says. ‘But the potential is real. The body has been doing this for millions of years. We just need to learn how to listen to it.’

Until then, menstrual blood remains a powerful, underused resource. It holds untapped potential—not just for reproductive health, but for understanding how the body heals itself. As more research is conducted and more funding is directed toward women’s health, the future of menstrual blood diagnostics may well be one of the most transformative advances in women’s health in the coming decades.

Sources & further reading

Featured image: original publisher image. Via original publisher. Image source

Show More

Related Articles

Back to top button